Diabetes and Dyslipidemia

Slides:



Advertisements
Similar presentations
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Advertisements

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.
Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
First time a CETP inhibitor shows reduction of serious CV events
The Latest Lipid Guidelines:
Classification of total cholesterol levels
Scandinavian Simvastatin Survival Study (4S)
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Neil J. Stone et al. JACC 2014;63:
Cholesteryl Ester Transfer Protein Inhibitors
The Chemical Differences Between EPA and DHA.
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Advances in Dyslipidemia: What Have We Learned From ACC 2017
What Do We Know About LDL-C?
What Has Been Tried and What Is True?
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
The Chemical Differences Between EPA and DHA.
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
What's New in Dyslipidemia?
PCSK9 Inhibitors and Cardiovascular Outcomes
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
Improving Appropriate Access to PCSK9 Inhibitors
Statins and HIV:.
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Lipid Clinic Challenge
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Clinicians' Corner in Dyslipidemia
Updates in Cardiovascular Medicine
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Advances in Hypertriglyceridemia Treatment
I. Introduction American Journal of Kidney Diseases
OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
Contemporary Evidence-Based Guidelines
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Latest Lipid Guidelines in Perspective
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Reducing Risk for CV Outcomes
Potential mechanisms whereby statins may reduce the risk of stroke
New Lipid-Lowering Guidelines
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Addressing Cardiovascular Events:
Achieving Lipid Targets With PCSK9 Inhibition
Lipids, the Heart, and the Kidney
PCSK9 Inhibitors and Real-World Evidence
Shared-Decision Making in Dyslipidemia
Late-Breaking Data on LDL-C Reduction
Translating Data From Trial to Practice
Presentation transcript:

Diabetes and Dyslipidemia

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

IMPROVE-IT

2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia

Achieved LDL < 50 mg/dL Has a Greater Relative Risk Reduction Than Higher Levels

ACCORD Primary Outcome Event Rate

IMPROVE-IT Diabetes

ODYSSEY LONG TERM LDL lowering

ODYSSEY LONG TERM Safety

Coronary Atheroma Regression as a Function of LDL Lowering

Management of a Patient With SAMS Step V: Rechallenge the patient repetitively

ODYSSEY Alternative Study Design

ODYSSEY Alternative

ONGOING LIPID Lowering Trials

Post-hoc Adjudicated Cardiovascular TEAEs† Pooled From Phase 3 Placebo-controlled Trials

Cholesteryl Ester Transfer Protein Inhibitors A Note of Caution

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)